These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25512615)

  • 1. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma.
    Li Z; Sun Y; Chen X; Squires J; Nowroozizadeh B; Liang C; Huang J
    Mol Cancer Res; 2015 Mar; 13(3):584-91. PubMed ID: 25512615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.
    Chen H; Sun Y; Wu C; Magyar CE; Li X; Cheng L; Yao JL; Shen S; Osunkoya AO; Liang C; Huang J
    Endocr Relat Cancer; 2012 Jun; 19(3):321-31. PubMed ID: 22389383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.
    Mao JH; Perez-Losada J; Wu D; Delrosario R; Tsunematsu R; Nakayama KI; Brown K; Bryson S; Balmain A
    Nature; 2004 Dec; 432(7018):775-9. PubMed ID: 15592418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulated ERK1/2 MAP kinase signaling promotes aneuploidy by a Fbxw7β-Aurora A pathway.
    Duhamel S; Girondel C; Dorn JF; Tanguay PL; Voisin L; Smits R; Maddox PS; Meloche S
    Cell Cycle; 2016 Jun; 15(12):1631-42. PubMed ID: 27152455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
    Li N; Lorenzi F; Kalakouti E; Normatova M; Babaei-Jadidi R; Tomlinson I; Nateri AS
    Oncotarget; 2015 Apr; 6(11):9240-56. PubMed ID: 25860929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
    Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
    Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PC3 is a cell line characteristic of prostatic small cell carcinoma.
    Tai S; Sun Y; Squires JM; Zhang H; Oh WK; Liang CZ; Huang J
    Prostate; 2011 Nov; 71(15):1668-79. PubMed ID: 21432867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
    Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
    Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
    Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
    Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FBXW7 beta-form is suppressed in human glioma cells.
    Gu Z; Inomata K; Ishizawa K; Horii A
    Biochem Biophys Res Commun; 2007 Mar; 354(4):992-8. PubMed ID: 17274947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.
    Kalous O; Conklin D; Desai AJ; Dering J; Goldstein J; Ginther C; Anderson L; Lu M; Kolarova T; Eckardt MA; Langerød A; Børresen-Dale AL; Slamon DJ; Finn RS
    Breast Cancer Res Treat; 2013 Oct; 141(3):397-408. PubMed ID: 24091768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate.
    Heaphy CM; Haffner MC; Graham MK; Lim D; Davis C; Corey E; Epstein JI; Eisenberger MA; Wang H; De Marzo AM; Meeker AK; Lotan TL
    Hum Pathol; 2020 Jul; 101():70-79. PubMed ID: 32389660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B.
    Yu Z; Sun Y; She X; Wang Z; Chen S; Deng Z; Zhang Y; Liu Q; Liu Q; Zhao C; Li P; Liu C; Feng J; Fu H; Li G; Wu M
    J Hematol Oncol; 2017 Jun; 10(1):115. PubMed ID: 28595628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.
    Huang YH; Zhang YQ; Huang JT
    Asian J Androl; 2019; 21(3):291-295. PubMed ID: 30924452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-92a is upregulated in cervical cancer and promotes cell proliferation and invasion by targeting FBXW7.
    Zhou C; Shen L; Mao L; Wang B; Li Y; Yu H
    Biochem Biophys Res Commun; 2015 Feb; 458(1):63-9. PubMed ID: 25623537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.
    Sun F; Zhang ZW; Tan EM; Lim ZLR; Li Y; Wang XC; Chua SE; Li J; Cheung E; Yong EL
    Carcinogenesis; 2016 Jul; 37(7):701-711. PubMed ID: 27207661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
    Hansel DE; Nakayama M; Luo J; Abukhdeir AM; Park BH; Bieberich CJ; Hicks JL; Eisenberger M; Nelson WG; Mostwin JL; De Marzo AM
    Prostate; 2009 May; 69(6):603-9. PubMed ID: 19125417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer.
    Xu P; Yang JC; Chen B; Ning S; Zhang X; Wang L; Nip C; Shen Y; Johnson OT; Grigorean G; Phinney B; Liu L; Wei Q; Corey E; Tepper CG; Chen HW; Evans CP; Dall'Era MA; Gao AC; Gestwicki JE; Liu C
    Nat Commun; 2024 Aug; 15(1):6626. PubMed ID: 39103353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma.
    Wei S; Lin LF; Yang CC; Wang YC; Chang GD; Chen H; Chen CS
    Mol Pharmacol; 2007 Sep; 72(3):725-33. PubMed ID: 17569795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine differentiation of prostate cancer.
    Li Z; Chen CJ; Wang JK; Hsia E; Li W; Squires J; Sun Y; Huang J
    Asian J Androl; 2013 May; 15(3):328-32. PubMed ID: 23503426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.